New York, May 22, 2026, 09:01 EDT
- Decoy Therapeutics holders who owned shares at the end of trading Friday can vote at the company’s annual meeting on July 14.
- DCOY is still a thinly traded micro-cap biotech. Price feeds showed a sharp move in the stock this week.
- The latest quarterly filing from the company listed $7.8 million in cash and restricted cash, a net loss of $2.2 million for the first quarter, and included “substantial doubt” about its ability to stay in business.
Decoy Therapeutics Inc. (DCOY) was active ahead of Friday’s open with the company hitting the record date for its 2026 annual meeting. The governance step comes with DCOY shares coming off a choppy week.
Decoy, based in Houston, said shareholders on record as of May 22 can vote at its annual meeting on July 14. The record date sets which shareholders can vote. Decoy said in a filing that proposals and director nominations must be in by the close of business May 29.
That’s an issue now since Decoy is still working to steady itself in the public markets after going through a merger, a new name, a reverse split, and Nasdaq compliance problems earlier this year. It also gives shareholders a short-term shot at governance before the company sends in its proxy statement to the SEC.
DCOY last traded at $6.43 on TradingView, up 15.65% for the session. Over the past five days, the stock gained 42.89% but is still down 95.36% for the year. Robinhood listed DCOY at $6.26 right before the open. Average daily volume is around 12,260 shares, which is low and can lead to sharp price swings. TradingView
Decoy is a preclinical biotech, so none of its products are in human trials yet. The company says it’s using machine learning and AI, along with rapid synthesis, to make peptide conjugate drug candidates. These are drugs linked to peptides—short amino acid chains—to target disease biology.
Decoy said in its latest quarterly filing it had $7.8 million in cash and equivalents as of March 31, posted a net loss of $2.2 million for the first quarter, and reported no product sales. The company said it expects its current cash to fund its “current and restructured operations into late 2026.” SEC
But funding is the question. Decoy said recurring losses and no product revenue create “substantial doubt” about staying a going concern—accounting language for doubt about survival without new capital. The company may try to get equity or debt, or look to partnerships or collaborations. If it can’t raise cash “in the very near term,” Decoy said it might have to shut down, sell assets and wind up the business. SEC
Nasdaq listing concerns are still out there. Decoy said in March it was back in compliance with the $1 minimum bid price rule, after enacting a reverse stock split to boost its share price. The company is still being monitored by a Nasdaq panel until March 31, 2027.
Decoy CEO Rick Pierce said the company is pushing its pipeline fast toward the clinic. “We are executing with urgency and purpose as we advance our pipeline assets to the clinic as expeditiously as possible,” Pierce said in a company statement April 9 that laid out Decoy’s antiviral milestones. PR Newswire
Decoy is earlier in the development cycle than Cocrystal Pharma and Atea Pharmaceuticals, both calling themselves clinical-stage antiviral firms. That matters for investors. Decoy’s value isn’t about current revenue, but whether it can fund studies, select lead drugs and file for an IND, the U.S. application to start human trials. Cocrystalpharma
Nasdaq is open for a normal Friday, ahead of the Memorial Day break on Monday, May 25, when markets are closed. DCOY gets one more full trading day before the holiday and faces a May 29 deadline for shareholder proposals.
DCOY’s next step may not come down to the meeting date, but to what Decoy delivers on financing and drug-development milestones before its cash starts to run low. With a stock this thin, small news can shift the tape. Lack of news can also move it.
